TACROLIMUS EXTENDED-RELEASE CAPSULES

127607 reported adverse events

These side effects are most commonly reported by patients taking TACROLIMUS EXTENDED-RELEASE CAPSULES:

# Side effect Count
0 OFF LABEL USE 13196
1 DRUG INEFFECTIVE 9055
2 PRODUCT USE IN UNAPPROVED INDICATION 6165
3 DRUG INTERACTION 5630
4 ACUTE KIDNEY INJURY 5530
5 DIARRHOEA 4599
6 TRANSPLANT REJECTION 4151
7 CYTOMEGALOVIRUS INFECTION 4081
8 PYREXIA 3881
9 COVID-19 3756
See all common reactions for TACROLIMUS EXTENDED-RELEASE CAPSULES

TACROLIMUS EXTENDED-RELEASE CAPSULES is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CALCINEURIN INHIBITOR INDUCED PAIN SYNDROME 86 0.9348
1 NEW ONSET DIABETES AFTER TRANSPLANTATION 155 0.8960
2 MALACOPLAKIA 397 0.8668
3 TRANSPLANTATION ASSOCIATED FOOD ALLERGY 85 0.8416
4 SMOOTH MUSCLE CELL NEOPLASM 334 0.7990
5 TRICHODYSPLASIA SPINULOSA 303 0.7953
6 RENAL GRAFT INFECTION 183 0.7888
7 PHAEOHYPHOMYCOSIS 372 0.7766
8 POST TRANSPLANT DISTAL LIMB SYNDROME 152 0.7488
9 POLYOMAVIRUS-ASSOCIATED NEPHROPATHY 1736 0.7403
See all enriched reactions for TACROLIMUS EXTENDED-RELEASE CAPSULES